Drug Profile
DRGT 102
Alternative Names: DRGT-102Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Druggability Technologies
- Developer Tavanta Therapeutics
- Class Antifibrotics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Cystic-fibrosis in Ireland
- 01 Sep 2020 Druggability Technologies is now called Tavanta Therapeutics
- 08 Aug 2017 DRGT 102 is available for licensing as of 08 Aug 2017. http://www.drgtco.com/